Chapter title |
Neuropathological Assessment as an Endpoint in Clinical Trial Design
|
---|---|
Chapter number | 18 |
Book title |
Biomarkers for Alzheimer’s Disease Drug Development
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-7704-8_18 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7703-1, 978-1-4939-7704-8
|
Authors |
Steve Gentleman, Alan King Lun Liu |
Abstract |
Different neurodegenerative conditions can have complex, overlapping clinical presentations that make accurate diagnosis during life very challenging. For this reason, confirmation of the clinical diagnosis still requires postmortem verification. This is particularly relevant for clinical trials of novel therapeutics where it is important to ascertain what disease and/or pathology modifying effects the therapeutics have had. Furthermore, it is important to confirm that patients in the trial actually had the correct clinical diagnosis as this will have a major bearing on the interpretation of trial results. Here we present a simple protocol for pathological assessment of neurodegenerative changes. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 2 | 67% |
Student > Ph. D. Student | 1 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 1 | 33% |
Medicine and Dentistry | 1 | 33% |
Unknown | 1 | 33% |